Merck Animal Health Statement on Bravecto

Updated June 23, 2015
Nothing is more important to Merck Animal Health than the safety and efficacy of our products, and the health and well-being of animals. As you may be aware, a post on a social media site about Bravecto circulated earlier this month.
As a responsible animal health company, we take every report seriously and investigate thoroughly. We are working diligently to gather information through all means possible, but please be aware that details for all pharmacovigilance cases are confidential. Thus, we don’t disclose information specific to any report.
In the meantime, we want to reiterate the safety of BRAVECTO.

• Merck Animal Health is confident in the safety of BRAVECTO, which has been established through a comprehensive clinical research program as well as through extensive post-marketing surveillance.
• BRAVECTO has been prescribed to millions of dogs around the world, and reports of adverse events have been extremely low and consistent with the product label.
• Regulatory agencies around the world have consistently affirmed that BRAVECTO is safe for use as indicated in its label.

Again, our commitment is to the health and well-being of pets, and addressing this situation is a priority.
IMPORTANT SAFETY INFORMATION: The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. Bravecto has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. Bravecto is not effective against lone star ticks beyond 8 weeks after dosing. For full prescribing information, click here.